Alnylam Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2836 www.alnylam.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal - Mar 12th, 2026 5:13 am
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Mar 11th, 2026 2:05 pm
Alnylam to Webcast TTR Investor Webinar - Mar 10th, 2026 6:00 am
Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation - Mar 7th, 2026 10:09 am
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Mar 7th, 2026 12:07 am
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal - Mar 6th, 2026 5:19 am
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Mar 6th, 2026 3:13 am
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - Mar 5th, 2026 7:05 am
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Mar 5th, 2026 6:30 am
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)? - Mar 5th, 2026 1:13 am
Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals - Mar 4th, 2026 4:19 pm
Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight - Mar 4th, 2026 4:01 pm
Blackstone puts $400M into Teva, Sanofi gut disease drug - Mar 4th, 2026 4:57 am
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors - Mar 3rd, 2026 7:00 am
Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. - Mar 2nd, 2026 9:39 pm
Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - Mar 2nd, 2026 6:01 am
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Mar 2nd, 2026 2:05 am
Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock - Feb 28th, 2026 11:33 pm
Does Alnylam Pharmaceuticals (ALNY) Price Reflect Its RNAi Pipeline Potential? - Feb 27th, 2026 9:26 pm
GSK Strikes $1 Billion China RNA Deal - Feb 24th, 2026 9:43 am